European Union Requires NAION Warnings for Semaglutide In June 2025, the European Medicines Agency (EMA) required semaglutide products Ozempic, Wegovy and Rybelsus to include a warning that the medications may cause a very rare increased risk of NAION
For instance, in August 2024, Eli Lilly and Company announced positive topline results from the SURMOUNT-1 trial, a three-year study evaluating the effectiveness and safety of tirzepatide (marketed as Zepbound and Mounjaro) administered once weekly for long-term weight management and delaying the progression to diabetes in adults with pre-diabetes and obesity or overweight
Interest in medical weight management continues to grow as more people seek options that support long term results
Individuals recovering from athletic injuries or physical trauma Those experiencing ongoing joint pain or arthritis Patients managing chronic inflammation or tissue damage Active individuals seeking quicker recovery between activities Anyone addressing gut health or nerve-related concerns Take control of your healing and activate your bodys natural recovery abilities
In mid-2023, reports of suicidal ideation and behavior in patients taking GLP-1s prompted regulators around the world to look into such risk
It is not classified as a controlled substance and can be safely used in medical settings
